Bavaria-based mbiomics secured a €30 million Series A round, with the latest closing at €12 million, marking its transition from platform development to clinical execution. The funds will advance their microbiome-based therapeutics platform, including scalable manufacturing and clinical translation of their lead candidate, MBX-116, for oncology. Existing investors MIG Fonds and Bayern Kapital participated in the round.
Amount: $12.0M
